within Pharmacolibrary.Drugs.ATC.J;

model J06BB09
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 6.666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 8e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J06BB09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cytomegalovirus immunoglobulin (CMV-IG) is a purified, sterile solution of immunoglobulin G (IgG) containing high titers of antibodies specific to cytomegalovirus. It is used primarily for the prophylaxis of cytomegalovirus disease, especially in solid organ transplant recipients and immunocompromised patients. It is approved and in use today in specific clinical circumstances.</p><h4>Pharmacokinetics</h4><p>PK parameters in adult solid organ transplant recipients based on information from manufacturer product characteristics; lacks robust published, peer-reviewed PK studies.</p><h4>References</h4><ol><li><p>Echenique, IA, et al., &amp; Agrawal, N (2017). Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. <i>Transplantation proceedings</i> 49(7) 1560–1564. DOI:<a href=\"https://doi.org/10.1016/j.transproceed.2017.02.046\">10.1016/j.transproceed.2017.02.046</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28838440/\">https://pubmed.ncbi.nlm.nih.gov/28838440</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J06BB09;
